MedPath

Evaluation of Egg Consumption and Its Enrichment With Annatto on Cardiovascular Risk and Satiety in Healthy Adults

Not Applicable
Completed
Conditions
Healthy Volunteers
Interventions
Dietary Supplement: Whole egg
Dietary Supplement: Annatto-enriched egg
Dietary Supplement: Egg whites - Control
Registration Number
NCT05088577
Lead Sponsor
Universidad de Antioquia
Brief Summary

Healthy adult volunteers (n= 105; 18-59 years) were randomly allocated to consume daily for 8 weeks, either two whole eggs (egg group), two whole eggs added with annatto (annatto-enriched egg group), or two egg whites (control). Volunteers were asked to continue with the habitual physical activity and diet, except for the consumption of additional eggs, egg whites or annatto.

It is hypothesized that participants consuming eggs would have a less atherogenic lipid profile, feel more satisfied and increase antioxidant levels in blood, compared to the control group. Participants in the annatto-enriched egg group would have greater antioxidant capacity than the egg group and compared to control.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
105
Inclusion Criteria
  • Age: 18-59 years
  • Body Mass Index (BMI): 18,5 - 29,9 kg/m2
  • Healthy volunteers
  • Good disposition to consume either eggs, egg whites or eggs added with annatto
  • To have signed the informed consent
Exclusion Criteria
  • Fasting blood triglycerides > 500mg/dL, Total Cholesterol > 240mg/dL, glucose > 126mg/dL or diabetes.
  • Blood pressure: >140/90 mmHg.
  • History or having any of the following: liver, kidney, or heart disease, cancer, endocrine or gastrointestinal disorders -especially those that limit food absorption.
  • Use of medications to lower blood lipids or glucose.
  • Consumption of multivitamins or nutraceuticals.
  • Plan to lose body weight, pregnancy or breastfeeding.
  • Any known allergy or intolerance to eggs or annatto.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Whole eggWhole eggTwo whole eggs (50g each) to be eaten daily during 8 weeks
Annatto-enriched eggAnnatto-enriched eggTwo whole eggs (50g each) enriched with annatto (Bixa orellana L.) to be eaten daily during 8 weeks. Dose of annatto: 1,2 mg bixin/kg of body weight.
Egg whites - ControlEgg whites - ControlTwo egg whites to be eaten daily during 8 weeks
Primary Outcome Measures
NameTimeMethod
Blood lutein levelsChange from Baseline Blood lutein levels at 8 weeks

Fasting blood lutein levels in micrograms per mL

Blood bixin levelsChange from Baseline Blood bixin levels at 8 weeks

Fasting blood bixin levels in %

Apolipoprotein B (ApoB)Change from Baseline ApoB at 8 weeks

Fasting blood ApoB in mg/L measured by Nuclear Magnetic Resonance

Total cholesterolChange from Baseline Total cholesterol at 8 weeks

Fasting blood total cholesterol in mg/dL

Systolic Blood PressureChange from Baseline Systolic Blood Pressure at 8 weeks

Systolic blood pressure in mmHg will be used to present the results of this variable, as follow: e.g. 130 mmHg

TriglyceridesChange from Baseline Triglycerides at 8 weeks

Fasting blood triglycerides in mg/dL

Very low-density lipoprotein (VLDL) cholesterolChange from Baseline VLDL cholesterol at 8 weeks

Fasting blood VLDL cholesterol in mg/dL

Body Mass Index (BMI) in kg/m^2: weight in kilograms, height in metersChange from Baseline BMI at 8 weeks

weight and height will be combined to report BMI in kg/m\^2

Low-density lipoprotein (LDL) cholesterolChange from Baseline LDL cholesterol at 8 weeks

Fasting blood LDL cholesterol in mg/dL

Waist circumferenceChange from Baseline Waist circumference at 8 weeks

Waist circumference in centimeters measured at the superior border of the iliac crest

Triglyceride-Rich lipoprotein (TRLP) sizeChange from Baseline TRLP size at 8 weeks

Fasting blood subclasses (Large, medium, small) of TRLP in nmol/L measured by Nuclear Magnetic Resonance

Low-density lipoprotein (LDL) sizeChange from Baseline LDL size at 8 weeks

Fasting blood subclasses (Large, medium, small) of LDL in nmol/L measured by Nuclear Magnetic Resonance

High-density lipoprotein (HDL) sizeChange from Baseline HDL size at 8 weeks

Fasting blood subclasses (Large, medium, small) of HDL in μmol/L measured by Nuclear Magnetic Resonance

High-density lipoprotein (HLDL) cholesterolChange from Baseline HDL cholesterol at 8 weeks

Fasting blood HLDL cholesterol in mg/dL

GlucoseChange from Baseline Glucose at 8 weeks

Fasting blood glucose in mg/dL

Diastolic Blood PressureChange from Baseline Diastolic Blood Pressure at 8 weeks

Diastolic blood pressure in mmHg will be used to present the results of this variable, as follow: e.g. 85 mmHg

GhrelinChange from Baseline Ghrelin at 8 weeks

Ghrelin in pg/mL

Visual Analog Scale (VAS) to Measure Perceived Hunger and SatietyChange from Baseline VAS of Hunger and Satiety at 8 weeks

"Visual Analog Scale to measure perceived hunger and satiety" to complete in the morning, fasting, 5 days before entering the study and the last 5 days to end the study (8th week). The VAS consist of 8 questions followed each by a line of 10cm in which the person marks a position corresponding to his/her feelings about hunger and satiety. A higher score (10) means the person feels with more hunger or satisfied.

Dietary lutein+zeaxanthin levelsChange from Baseline Dietary lutein+zeaxanthin levels at 8 weeks

Dietary lutein+zeaxanthin levels in micrograms

Apolipoprotein A1 (ApoA1)Change from Baseline ApoA1 at 8 weeks

Fasting blood ApoA1 in mg/L measured by Nuclear Magnetic Resonance

Secondary Outcome Measures
NameTimeMethod
Ancestry Informative MarkerBaseline

Percentage of genetic ethnicity of European, Amerindian and African for each participant

Trial Locations

Locations (1)

Sede de Investigación Universitaria - Universidad de Antioquia

🇨🇴

Medellín, Antioquia, Colombia

© Copyright 2025. All Rights Reserved by MedPath